SecBot SecBot
144 ·Filed Aug 17, 2026

MBX

MBX Biosciences, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed2mo ago SEC0001959173-26-006112
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-related sale by a former officer following equity vesting—no negative signal. Monitor for any Form 4 filings confirming the sale, but ignore for trading decisions.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
MBX ▼ -10.51% at T+20d
NEUTRAL call -10.51% · α vs SPY -8.53% · entry $68.25 → $61.08
Next anchor: T+60d in 15d
Latest observation: T+48 -50.22% FF3 residual α
Entry = T+0 close
Aug 17, 2026
via day close
T+1d
-2.53%
call -2.53% · α -1.86%
$66.52
settled 2mo ago
T+5d
-2.73%
call -2.73% · α -1.53%
$66.39
settled 2mo ago
T+20d
-10.51%
call -10.51% · α -8.53%
$61.08
settled 6w ago
T+60d
Pending
in 15d

Price Chart

Loading chart...

Executive Summary

Former officer Peter K. Hawryluk filed a Form 144 notice of intent to sell 3,745 MBX shares (~$256K at filing). The shares originated from restricted stock vesting on August 14, 2026, and the filing notes a prior sale on August 4, 2026 (936 shares, ~$62K) related to tax withholding on vested equity. This is a small, tax-motivated sale by a former officer—routine and not indicative of negative business sentiment.

Key Facts

  • Form 144 filed August 17, 2026, for sale of 3,745 shares of MBX common stock.
  • Shares originate from restricted stock vesting on August 14, 2026.
  • Proposed selling price ~$68.28/share, aggregate market value ~$255,737.
  • Prior related sale of 936 shares (~$61,563) on August 4, 2026, for tax withholding on equity award settlement.
  • Selling broker Fidelity Brokerage Services LLC; seller listed as former officer.

Financial Impact

~$256K proposed sale, ~0.008% of MBX's ~$3.3B market cap

insider holdings

Risk Factors

  • Further insider sales by other officers could accumulate, but this filing is isolated and small.
  • Form 144 indicates intent only; actual sale may not occur.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-006112
Document: 0001959173-26-006112-index.html0001959173-26-006112
Document: 0001959173-26-006112.txt0001959173-26-006112
27 reports for MBX
Performance horizon
70% Hit rate @ T+1 7 of 10 directional calls Went positive at some point 8 of 10 best @ T+60▲ +85.57%May 7, 2026
Filters
Rows
Reports for MBX — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
3
NEUTRAL ★ 2/10
$50.46 $48.50▼ −3.88%▼ −3.36%$50.29 (−0.34%)
Oct 22, 2026
4d ago
8-K
NEUTRAL ★ 2/10
$50.46 $48.50▼ −3.88%▼ −3.36%$50.29 (−0.34%)
Aug 27, 2026
8w ago
Press Release
BULLISH ★ 8/10
$66.39 $63.00▼ −5.11%▼ −4.88%$50.29 (−24.25%)
Aug 17, 2026
10w ago
144
NEUTRAL ★ 3/10
$68.25 $66.52▼ −2.53%▼ −1.86%$50.29 (−26.32%)
Aug 6, 2026
11w ago
8-K
BULLISH ★ 7/10
$67.11 $67.82▲ +1.06%▲ +0.45%$50.29 (−25.06%)
Jun 12, 2026
19w ago
8-K
BULLISH ★ 7/10
$35.51 $38.98▲ +9.77%▲ +8.01%$50.29 (+41.62%)
Jun 12, 2026
19w ago
Press Release
BULLISH ★ 6/10
$35.51 $38.98▲ +9.77%▲ +8.01%$50.29 (+41.62%)
Jun 11, 2026
19w ago
Institutional Cluster
BULLISH ★ 5/10
$37.25 $35.51▼ −4.67%▼ −5.21%$50.29 (+35.01%)
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 3/10
$37.25 $35.51▼ −4.67%▼ −5.21%$50.29 (+35.01%)
Jun 10, 2026
19w ago
144
NEUTRAL ★ 2/10
$30.99 $37.25▲ +20.20%▲ +18.50%$50.29 (+62.28%)
Showing 10 of 27

US Market Status

Market Closed — Opens Tue (16h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026